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Background: Adenosine is a potent endogenous anti-inflammatory and immunoregulatory molecule. Despite its
promise, adenosine’s extremely short half-life in blood limits its clinical application. Here, we examined adenosine
N1-oxide (ANO), which is found in royal jelly. ANO is an oxidized product of adenosine at the N1 position of the
adenine base moiety. We found that it is refractory to adenosine deaminase-mediated conversion to inosine. We
further examined the anti-inflammatory activities of ANO in vitro and in vivo.
Methods: The effect of ANO on pro-inflammatory cytokine secretion was examined in mouse peritoneal
macrophages and the human monocytic cell line THP-1, and compared with that of adenosine, synthetic adenosine
receptor (AR)-selective agonists and dipotassium glycyrrhizate (GK2). The anti-inflammatory activity of ANO in vivo
was examined in an LPS-induced endotoxin shock model in mice.
Results: ANO inhibited secretion of inflammatory mediators at much lower concentrations than adenosine and
GK2 when used with peritoneal macrophages and THP-1 cells that were stimulated by LPS plus IFN-γ. The potent
anti-inflammatory activity of ANO could not be solely accounted for by its refractoriness to adenosine deaminase.
ANO was superior to the synthetic A1 AR-selective agonist, 2-chloro-N6-cyclopentyladenosine (CCPA), A2A
AR-selective agonist, 2-[p-(2-carboxyethyl)phenethylamino]-5’-N-ethylcarboxamideadenosine hydrochloride (CGS21680),
and A3 AR-selective agonist, N6-(3-iodobenzyl)adenosine-5’-N-methyluronamide (IB-MECA), in suppressing the secretion
of a broad spectrum of pro-inflammatory cytokines by peritoneal macrophages. The capacities of ANO to inhibit
pro-inflammatory cytokine production by THP-1 cells were comparable with those of CCPA and IB-MECA. Reflecting its
potent anti-inflammatory effects in vitro, intravenous administration of ANO significantly reduced lethality of LPS-induced
endotoxin shock. A significant increase in survival rate was also observed by oral administration of ANO. Mechanistic
analysis suggested that the up-regulation of the anti-inflammatory transcription factor c-Fos was, at least in part, involved
in the ANO-induced suppression of pro-inflammatory cytokine secretion.
Conclusions: Our data suggest that ANO, a naturally occurring molecule that is structurally close to adenosine but is
functionally more potent, presents potential strategies for the treatment of inflammatory disorders.
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shockIntroduction
Acute local inflammation is a healthy immune response
that protects the body from pathogens such as bacteria,
viruses, fungi, and other parasites. Dendritic cells and
macrophages encountering the pathogens are triggered
to release cytokines and chemokines. In acute-phase in-
flammation, these cytokines and chemokines increase* Correspondence: keizo.kono@hb.nagase.co.jp
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unless otherwise stated.blood flow and vascular permeability along with the accu-
mulation of fluid and leukocytes that are important for an
effective defense [1]. However, in a variety of chronic
pathological conditions, pro-inflammatory cytokines are
released at high levels and mediate systemic inflammatory
responses. These cytokines include IL-1, IL-6, IL-12, IL-23
and TNF-α. For instance, when TNF-α is released locally
and physiologically at low levels, it plays beneficial roles in
protective immune responses against infectious pathogens
by helping neutrophil migration to a site of infection.
However, when it is systemically released at high levels,This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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administrations of neutralizing antibodies against TNF-α
or IL-6 have been successful in patients with rheumatoid
arthritis, inflammatory bowel diseases and psoriasis [2-5].
Adenosine is a key molecule that regulates numerous
physiological processes by activating four G-protein-
coupled adenosine receptors (ARs), A1, A2A, A2B and
A3 ARs. The nature and magnitude of the effect of ad-
enosine on the cell depend on the extracellular adeno-
sine concentrations, receptor density and the functional
characteristics of the intracellular signaling pathways [6].
Adenosine is a potent endogenous anti-inflammatory
and immunoregulatory molecule [6,7]. When adenosine
is physiologically released from cells at sites of inflam-
mation or tissue injury, it regulates the immune and in-
flammatory systems and plays a central role in wound
healing by increasing angiogenesis through upregulating
vascular endothelial growth factor [6]. It is well accepted
that adenosine downregulates the release of pro-
inflammatory mediators primarily through A2A AR [8,9].
Furthermore, adenosine mediates the anti-inflammatory
effects of methotrexate [10]. Despite these beneficial prop-
erties, adenosine has an extremely short half-life because
of its rapid metabolism in blood due to conversion by ad-
enosine kinase to adenosine monophosphate (AMP) or its
change to inosine by adenosine deaminase. These conver-
sions prevent its clinical usage [7,11].
In this regard, the therapeutic benefit of AR-selective
agonists is fully appreciated and varieties of selective ag-
onists have been chemically synthesized. Using these
synthetic adenosine agonists, clinical trials have been
carried out, although some have been withdrawn due to
potential side-effects or poor bioavailability [12,13].
In addition to the anti-inflammatory action through acti-
vation of A2A AR, the three remaining ARs possess some
anti-inflammatory activity. For example, when an adeno-
sine A1R agonist was injected 24 h prior to challenge with
E. coli, upregulation of serum pro-inflammatory cytokines
and peritoneal leukocyte recruitment were inhibited,
thereby reducing the severity of peritonitis [14]. Moreover,
A2B AR-deficient mice failed to induce regulatory T cells
after endotoxin-induced pulmonary inflammation and
underwent enhanced recruitment of pro-inflammatory
effector T cells. Those results suggest that A2B AR
serves a potent anti-inflammatory role through the up-
regulation of regulatory T cells [15]. It has been shown
that methotrexate-induced adenosine downmodulates
acute inflammation by activating A2A and/or A3 ARs
[16]. These findings suggest that adenosine, as a physio-
logical agonist, has therapeutic potential for inflamma-
tory disorders through one or more of the ARs, if the
drawbacks of short half-life could be overcome.
We have previously shown that royal jelly (RJ) con-
tains low and high molecular weight substances (<5 kDaand >30 kDa, respectively) that can inhibit the secretion
of pro-inflammatory cytokines by activated macrophages
[17]. We previously isolated MRJP3 protein as a high
molecular weight anti-inflammatory substance [17].
Using multiple steps of chromatography, we also isolated
adenosine N1-Oxide (ANO), an anti-inflammatory sub-
stance from the low-molecular weight fraction of RJ. In
this study, the anti-inflammatory actions of ANO were
examined in vitro and in vivo and compared with those




BALB/c female mice, aged 8–12 weeks, were purchased
from Charles River Japan (Kanagawa, Japan). All animal
experiments described in this article were conducted ac-
cording to the guidelines on Animal Experimentation at
the R&D center of Hayashibara Co., LTD.
Reagents
RJ that had been collected from Anhui in China was
used. Lipopolysaccharide (LPS) (E. coli 055:B5), adenine,
adenosine, zymosan A, Wortmannin and adenosine de-
aminase were purchased from Sigma-Aldrich Japan
(Tokyo, Japan). Adenine N1-Oxide was purchased from
MP Biomedicals (Santa Ana, CA). GK2 was purchased
from Maruzen Pharmaceuticals (Hiroshima, Japan). Ad-
enosine deaminase inhibitor, erythro-9-(2-hydroxy-3-
nonyl) adenine hydrochloride (EHNA) was obtained
from Enzo Life Sciences (Farmingdale, NY). Pam3CSK4
was purchased from Bachem (King of Prussia, PA). Poly
I:C was purchased from Calbiochem (La Jolla, CA).
Murine recombinant interferon-γ (IFN-γ), human TNF-
α, and monoclonal antibodies (mAb) for human TNF-α
ELISA were prepared and purified in our laboratories.
Mouse cytokine standards for ELISA (TNF-α, IL-6, IL-
10, and IL-12) were obtained from BD Pharmingen (San
Diego, CA). The following pairs of mAbs for ELISA cap-
ture and biotinylated detection were purchased from BD
Pharmingen: TNF-α, G281-2626 and MP6-XT3; IL-6,
MP5-20 F3 and MP5-32C11; IL-10, JES5-2A5 and SXC-1;
and, IL-12 p70, 9A5 and C17.8.
A1 AR-selective agonist 2-chloro-N6-cyclopentyladeno-
sine (CCPA), A2A AR- selective agonist 2-[p-(2-carbox-
yethyl)phenethylamino]-5’-N-ethylcarboxamideadenosine
hydrochloride (CGS21680), A3 AR-selective agonist
N6-(3-iodobenzyl)adenosine-5’-N-methyluronamide (IB-
MECA), and A3 AR-selective antagonist 3-ethyl-5-ben-
zyl-2-methyl-4-phenylethynyl-6-phenyl-1,4-(±)-dihydropyr-
idine-3, 5-dicarboxylate (MRS1911) and adenosine were
purchased from Sigma-Aldrich Japan. A1 AR-selective an-
tagonist 8-cyclopentyl-1,3- dipropylxanthine (DPCPX),
A2A AR-selective antagonist 4-(2-[7-amino-2-(furan-2-yl)-
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(ZM241385), A2B AR-selective antagonist N-(4-cyano-
phenyl)-2-[4-(2, 3, 6, 7-tetrahydro-2, 6-dioxo-1, 3-dipropyl-
1H-purin-8-yl)phenoxy]-acetamide (MRS1754) were
purchased from Tocris Bioscience (Bristol, UK). N-[2-[[3-
(4-Bromophenyl)-2-propenyl]amino]ethyl]-5-isoquinoline-
sulfonamide dihydrochloride (H-89) was purchased from
Merck Millipore (Darmstadt, Germany).
Isolation of ANO from extracts of RJ
Fresh RJ was suspended in 200 mM Tris–HCl buffer,
pH 8.0. The supernatants of the RJ suspensions were col-
lected by centrifugation at 10,000×g for 15 min at 4°C.
The low-molecular weight fraction of RJ was prepared by
centrifugation (2,000×g) using an Ultrafree centrifugal fil-
ter device, with a molecular cut-off of 6 kDa. From the
low-molecular weight fraction of RJ, ANO was purified
to homogeneity by sequential purification on three types
of reversed-phase column chromatography: a Vydac
218TP510 column (Grace, Deerfield, IL), a TSKgel ODS-
80Ts column (Tosoh, Tokyo, Japan), followed by an YMC-
Pack ODA-A column (YMC, Kyoto, Japan). The yield of
ANO was 123 ± 25 μg per 1 g of RJ (mean ± S.D., n = 3).
ANO structure was characterized spectroscopically by 1H
and 13C NMR and electrospray ionization MS (ESI-MS):
ESI-MS m/z 284.15 [M+H]+; 1H-NMR (dimethylsul-
phoxide-d6, 300 MHz) δ ppm: 8.663 (s, 1H), 8.565 (s, 1H),
7.5 - 9.0 (br, 2H), 5.885 (d, J = 5.4, 1H), 5.546 (d, J = 4.8,
1H), 5.240 (d, J = 3.3, 1H), 5.059 (bs, 1H), 4.530 (bd, J = 4.8,
1H), 4.148 (bd, J = 3.0, 1H), 3.946 (bd, J = 3.6, 1H), 3.670
(m, 1H), 3.553 (m, 1H); and 13C-NMR (dimethylsulphox-
ide-d6, 300 MHz) δ ppm: 143.28, 142.41, 148.32, 141.92,
118.82, 87.43, 85.49, 73.75, 70.13, 61.15. Chemical shifts in
the ribose moiety of ANO were very close to those of ad-
enosine in both 1H-NMR and 13C-NMR analyses. Chemical
shifts in the adenine base moiety of ANO showed similar
patterns as those of adenosine monophosphate N1-oxide
(AMP N1-Oxide) reported previously [18].
Synthesis of ANO
ANO was prepared according to the procedure de-
scribed previously [19]. Adenosine (20 g) was suspended
in 1 L of acetic acid, and 100 mL of 30% hydrogen per-
oxide solution was added to the suspension. The mix-
tures were stirred for 5 days at room temperature. After
decomposing excess amounts of hydrogen peroxide by
adding 5 g of 5% palladium on carbon (Kawaken Fine
Chemicals, Tokyo, Japan) to the mixture, the palladium
on carbon was separated by filtration. The filtrate was
desiccated under reduced pressure. ANO crystallized
after adding ethanol to the residue and was isolated by
filtration. After repeated recrystallization from methanol,
8 g of ANO with 99.1% purity was obtained and used in
this study.Cell cultures and stimulation
Murine peritoneal macrophages were elicited by intra-
peritoneal injection of 2 mL 4% Brewer’s thioglycollate
medium (Nissui Pharmaceutical, Tokyo, Japan) into the
peritoneal cavities of BALB/c mice. Peritoneal exudate
cells were collected by lavage 3 to 4 days after injection.
Cells were washed twice and plated in 10-cm diameter
plastic dishes (Nippon Becton Dickinson, Tokyo, Japan)
at a density of 1 × 108 cells/dish in 10 mL of RPMI1640
medium (Nissui Pharmaceutical) containing 10% (v/v)
FBS (Life Technologies, Grand Island, NY). After 2 h incu-
bation at 37°C in a humidified atmosphere of 5% CO2 and
95% air, non-adherent cells were removed by rinsing.
RPMI1640 medium containing 10% FBS was then added to
the adherent cells that were recovered by scraping (Nippon
Becton Dickinson). The recovered cells were used as
macrophages. The murine macrophage-like cell line,
RAW264.7 and the human monocytic cell line, THP-1
were maintained in RPMI1640 medium containing 10%
FBS. THP-1 cells were cultured with 1 mM sodium bu-
tyrate for 4 days before being used in the experiments.
For pro-inflammatory cytokine production, peritoneal
macrophages were seeded at 5 × 104 cells per well in flat
bottom 96-well microtiter plates and stimulated with LPS
(1 μg/mL) with or without murine IFN-γ (muIFN-γ)
(10 IU/mL) in the presence or absence of various concen-
trations of ANO, adenosine, adenine, adenine N1-oxide,
or GK2 at 37°C for 24 h. In some experiments, peritoneal
macrophages were stimulated with TLR agonists. Sodium
butyrate-treated THP-1 cells (1 × 105 cells per well) were
stimulated with LPS (5 μg/mL) plus human IFN-γ
(huIFN-γ) (500 IU/mL) (termed LPS/huIFN-γ). In other
experiments, THP-1 cells were pretreated with AR-
selective antagonists 30 min before stimulation with LPS/
huIFN-γ in the presence or absence of 10 μM ANO. After
24 h, the culture supernatants were collected for the
measurement of cytokines and PGE2. PGE2 was measured
using an ELISA kit (Amersham Pharmacia Biotech, Tokyo,
Japan). The lower limits of detection were 16, 50, 25,
250, 16 and 50 pg/mL for human TNF-α, murine TNF-
α, IL-6, IL-10, IL-12 and PGE2, respectively.
For measurement of cell proliferation, 20 μL alamar-
Blue dye (Trek Diagnostic Systems, OH), a redox indica-
tor, was added to each microplate well for the last 2 to
3 h of the incubation period. Fluorescence intensity (FI)
was measured at 544 nm excitation wavelength and
590 nm emission wavelength.
Stability of ANO in the presence of adenosine deaminase
The stability of ANO and adenosine in culture medium
containing 10% FBS at 37°C was examined by quantify-
ing the concentrations at the end points of the different
incubation periods by reverse phase high pressure liquid
chromatography (HPLC) using an ODS AQ-303 column
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deaminase, EHNA, was added together with adenosine. In
separate experiments, ANO or adenosine was mixed with
6.7 U/L of adenosine deaminase enzyme in 53.3 mM po-
tassium phosphate buffer containing 0.003% bovine serum
albumin, and the mixtures were incubated for up to
60 min at 37°C. The time course of ANO or adenosine
conversion was analysed by reverse phase HPLC.
LPS-induced endotoxin shock studies
BALB/c mice were intravenously administered saline or
ANO just before intraperitoneal injection of LPS
(18 mg/kg) (n = 6 mice in each group). In a separate ex-
periment, ANO was administered orally 1 h before and
1 and 6 h after LPS injection (n = 8 mice in each group).
Survival of the mice was monitored for 3 days after LPS
injection. In a parallel experiment, blood samples were
collected from the abdominal aorta 2 h after the LPS in-
jection. Sera from mice were obtained after centrifuga-
tion for 10 min at 4°C and stored at - 80°C until
cytokine measurements were performed.
RNA extraction and quantitative real-time polymerase
chain reaction (PCR)
Briefly, RAW264.7 cells (1 × 106/mL) were stimulated
with LPS (2 μg/mL) in the presence or absence of
10 μM ANO in 6-well plates, and incubated for 0.5 to
3 h at 37°C in 5% CO2. Total RNA was extracted from
RAW264.7 cells using an RNeasy Mini kit (QIAGEN,
Tokyo, Japan) and DNase (QIAGEN) according to the
manufacturer’s instructions. Subsequently, first-strand
cDNA was synthesized using Superscript® VILO™ cDNA
synthesis kit (Life Technologies, Carlsbad, CA). Specific
primers for PCR analysis of c-fos were identical to those
described previously [20]. PCR assay was carried out
with the following sense and antisense primers: c-fos
[GenBank: NM_010234], CGAAGGGAACGGAATAA-
GAT and GCAACGCAGACTTCTCATC; Gapdh [Gen-
Bank: NM_008084], ACCATCTTCCAGGAGCGAG and
AGTGATGGCATGGACTGTGG. Synthesized cDNA was
mixed with SYBR Green Master Mix (Roche, Mannheim,
Germany) and different sets of gene-specific primers.
Real-time PCR was performed using a LightCycler 480
system (Roche). For quantitative purposes, the expres-
sion of the c-fos gene was normalized to a house keep-
ing gene, Gapdh.
Western immunoblot analysis of cell signaling molecules
RAW264.7 cells were stimulated with LPS (2 μg/mL) in
the presence or absence of various concentrations of
ANO for 30 min at 37°C. Cellular proteins were
prepared in lysis buffer (20 mM Tris–HCl, pH 7.5 con-
taining 0.15 M NaCl, 1 mM EDTA, 0.1% SDS, 1% Triton
X-100, 0.5% sodium deoxycholate and inhibitors ofproteases and phosphatases). Nuclei and cell debris were
removed by centrifugation at 500 g for 10 min. Cell
lysates (20 μg) were separated by sodium dodecyl
sulfate-polyacrylamide gel electrophoresis (SDS-PAGE)
(Multigel 10/20; COSMO Bio, Tokyo, Japan) under re-
ducing conditions, and transferred to polyvinylidene
difluoride (PVDF) membranes (Merck Millipore Japan,
Tokyo, Japan) by electrophoretic transfer. PVDF mem-
branes were then blocked with a solution containing
10% Block Ace (Dainippon Pharmaceutical, Osaka,
Japan) for 0.5 h, and incubated with anti-c-Fos mAb
(9 F6; Cell Signaling Technology, Danvers, MA) for 1 h.
After washing the primary mAb, membranes were
washed three times with Tris-buffered saline containing
0.05% Tween 20, and then incubated with a 1:1000 dilu-
tion of secondary Ab conjugated to horseradish peroxid-
ase (Dako) for 1 h. The membranes were then washed
three times and reaction products visualized using the
enhanced chemiluminescence Western blot system
(Amersham). The same membrane was stripped and
reprobed with anti-c-Jun mAb (60A8; Cell Signaling
Technology) and anti-β-actin (ACTBD11B7; Santa Cruz
Biotechnology, Santa Cruz, CA), and then subjected to
Western blotting analysis as described above.Statistical analysis
Statistical analysis of the data was performed by Dunnett’s
test as appropriate. Survival differences were evaluated with
the log-rank tests using Kaplan-Meier survival curves. P-
values < 0.05 were considered statistically significant.Results
ANO inhibited IL-6 secretion by macrophages in response
to pathogen-associated molecular patterns
During our screening program to identify substance(s)
that inhibited secretion of pro-inflammatory cytokines,
we isolated ANO from the low-molecular weight frac-
tion of RJ. We then examined the effects of ANO on
pro-inflammatory cytokine production by macrophages
activated by their recognition of pathogen-associated
molecular patterns (PAMPs) via Toll-like receptors
(TLRs). Towards that end, the following activators were
used: LPS (TLR4 agonist), poly I:C (TLR3 agonist),
Pam3CSK4 (TLR 1/2 agonist) or zymosan A (TLR2
agonist). Exposure of murine peritoneal macrophages to
these PAMPs induced secretion of substantial amounts
of IL-6. When ANO was added to the culture in the
presence of the bacterial and viral PAMPs, IL-6 secretion
was significantly inhibited in a dose-dependent fashion
(Figure 1). Since the macrophage growth curve was not
parallel to the IL-6 inhibition curve, the inhibition was












































































Figure 1 ANO inhibited IL-6 production by peritoneal macrophages stimulated with TLR agonists. Peritoneal macrophages (5 × 104/well)
were stimulated with LPS (2 μg/mL) (A), Poly I:C (50 μg/mL) (B), Pam3CSK4 (5 μg/mL) (C) and zymosan A (100 μg/mL) (D) in the presence or
absence of various concentrations of ANO at 37°C for 24 h. Levels of IL-6 in the culture supernatants were determined by ELISA. Growth of
macrophages was assessed by adding 20 μl/well of alamarBlue™ dye for the last 2 to 3 h of the incubation period and expressed as FI values.
Values represent the means ± S.D. of triplicate cultures. Results are representative of two separate experiments with similar results. *p < 0.05;
**p < 0.01, significantly different when compared with control culture.
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adenosine and dipotassium glycyrrhizate
ANO is an oxidized product of adenosine at the N1
position of the adenine moiety. To explore the rela-
tionship between structure and activity, we compared
the inhibitory effects of ANO on pro-inflammatory
cytokine production with those of adenosine, adenine
and adenine N1-oxide. For this purpose, murine peri-
toneal macrophages were stimulated with 1 μg/mL
LPS plus 10 IU/mL murine IFN-γ (LPS/muIFN-γ) to
induce multiple pro-inflammatory mediators. IFN-γ
primes macrophages, enhancing their response to LPS
[21]. Moreover, IFN-γ is a critical mediator of endo-
toxin hypersensitivity induced by bacteria [22].
Figure 2A and B show the dose–response curves of
the inhibitory effects of ANO and related compounds
on the release of TNF-α and IL-6. ANO efficiently
inhibited both TNF-α and IL-6 production in a dose-
dependent fashion. Although minimal inhibition ofmacrophage growth was observed at 1 μM ANO, sig-
nificant reductions in the production of both TNF-α
and IL-6 were observed at concentrations that had no
effect on macrophage growth. Therefore, it seems likely
that inhibition of pro-inflammatory cytokines by ANO
was not due to a reduction of cell proliferation
(Figure 2C). Adenosine also inhibited the secretion of
both TNF-α and IL-6 in a dose-dependent manner,
but much higher concentrations were required to
achieve reductions observed with ANO (Figure 2A
and B). Unexpectedly, adenine significantly inhibited
the release of TNF-α at 10 times higher concentra-
tions than adenosine. IL-6 production was also
significantly inhibited by adenine, while no clear
dose–response effect was observed. Addition of adenine
N1-oxide also resulted in reduction of both TNF-α and
IL-6. However, the inhibitory action of adenine N1-oxide





































Figure 2 Inhibitory effects of ANO, adenosine, adenine and adenine N1-oxide on TNF-α and IL-6 secretion by LPS/muIFN-γ-stimulated
peritoneal macrophages. Peritoneal macrophages (5 × 104/well) were stimulated with LPS (1 μg/mL) and muIFN-γ (10 IU/mL) in the presence or
absence of various concentrations of ANO, adenosine, adenine and adenine N1-oxide at 37°C for 24 h. Levels of TNF-α (A) and IL-6 (B) in the
culture supernatants and growth of macrophages (C) were determined as described in Figure 1. Values represent the means ± S.D. of quadruplicate
cultures. Results are representative of two separate experiments with similar results. *p < 0.05; **p < 0.01, significantly different when compared with
control culture.
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GK2 (a broadly used anti-inflammatory drug) on the re-
lease of multiple pro-inflammatory mediators such as
TNF-α, IL-6, IL-12 and prostaglandin E2 (PGE2) by peri-
toneal macrophages in response to LPS/muIFN-γ. ANO
efficiently reduced the release of these pro-inflammatory
molecules in a dose-dependent fashion. Inhibition of pro-
inflammatory mediators was also observed with GK2, al-
though to a much lesser extent than ANO. In accordance
with a previous report [23], GK2 had a bimodal effect on
PGE2 production.
In addition, ANO exhibited more potent inhibitory ef-
fects than adenosine and GK2 on the secretion of both
TNF-α and IL-6 by LPS/huIFN-γ-stimulated THP-1
cells. The EC50s for ANO-, adenosine-, and GK2-
induced inhibition of TNF-α secretion were 4.9 μM,
55 μM, and 910 μM, respectively. The EC50s for ANO-,
adenosine-, and GK2-induced inhibition of IL-6 secre-
tion were 4.9 μM, 40 μM, and 1,000 μM, respectively.ANO is refractory to deamination by adenosine
deaminase
Adenosine deaminase irreversibly converts adenosine
to inosine. Since adenosine deaminase is present in
serum, the stability of ANO and adenosine in culture
medium supplemented with 10% FBS was examined.
As shown in Figure 4A, 10 μM ANO was stable over a
period of 24 h, whereas the same concentration of ad-
enosine was rapidly degraded and was not found in the
medium at the end of a 6 h incubation period. Con-
versely, the levels of inosine in the culture medium
increased. When 10 μM adenosine was incubated in
the presence of the adenosine deaminase inhibitor,
EHNA (10 μM), degradation of adenosine was not
observed (Figure 4A). We then compared the reactiv-
ities of ANO and adenosine to adenosine deaminase
(Figure 4B). Whereas adenosine rapidly disappeared
after incubation with adenosine deaminase, no change





















Figure 3 Inhibitory effects of ANO and GK2 on the release of inflammatory mediators by LPS/muIFN-γ-stimulated peritoneal
macrophages. Peritoneal macrophages (5 × 104/well) were stimulated with LPS (1 μg/mL) and muIFN-γ (10 IU/mL) in the presence or absence of
various concentrations of ANO and GK2 at 37°C for 24 h. Levels of TNF-α (A), IL-6 (B), IL-12 (C) and PGE2 (D) in the culture supernatants were
determined by ELISA. Values represent the means ± S.D. of triplicate cultures. Results are representative of two separate experiments with similar
results. *p < 0.05; **p < 0.01, significantly different when compared with control culture.
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amination by adenosine deaminase.
Next, we examined whether the difference in anti-
inflammatory activities in vitro between ANO and adeno-
sine could be ascribed to the refractoriness to adenosine
deaminase. For this purpose, peritoneal macrophages were
stimulated with LPS in the presence or absence of various
concentrations of ANO or adenosine with or without
10 μM EHNA. As shown in Figure 4C and D, the inhibi-
tory activity of adenosine on both TNF-α and IL-6 secre-
tion was increased by the addition of EHNA but was still
inferior to that of ANO.
Comparison of ANO and AR-selective agonists for their
capacities to inhibit pro-inflammatory cytokine production
A large number of AR-selective agonists have been
chemically synthesized, some of which are under evalu-
ation in clinical trials [13]. We compared the inhibitory
potencies of ANO and three AR-selective agonists(CCPA for A1 AR agonist, CGS21680 for A2A AR agon-
ist, and IB-MECA for A3 AR agonist). For this purpose,
murine peritoneal macrophages were stimulated for
24 h with LPS/muIFN-γ in the presence or absence of
ANO or the three agonists, and pro-inflammatory cyto-
kines secreted into culture medium were determined.
A2B AR-selective agonist with an adenosine-like struc-
ture is currently unavailable. As shown in Figure 5A,
ANO and three AR-selective agonists all inhibited TNF-
α secretion in a dose-dependent manner. Among the
four agents, CGS21680 was most effective, especially at
concentrations below 0.5 μM. TNF-α inhibitory poten-
cies of ANO and IB-MECA were comparable. CCPA
was less effective, but significantly inhibited TNF-α pro-
duction, although CCPA is an A1 AR-selective agonist.
In particular, ANO efficiently inhibited the release of
both IL-6 and IL-12 production (Figure 5A). Interest-
ingly, both CCPA and CGS21680 increased rather than



































































Figure 4 ANO was refractory to deamination by adenosine deaminase. Stability of 10 μM ANO or adenosine in RMPM 1640 medium
supplemented with 10% FBS was assessed in the presence or absence of EHNA (10 μM) for up to 24 h at 37°C. Concentrations of ANO,
adenosine or inosine at selected time points were quantified by HPLC (A). Reactivity of 10 μM ANO or adenosine with 6.7 U/L of adenosine
deaminase enzyme was assessed for up to 60 min at 37°C in 53.3 mM potassium phosphate buffer containing 0.003% bovine serum albumin.
Data are expressed as percentages of residual amounts of ANO or adenosine at each point in time (B). Anti-inflammatory effects of adenosine in
the presence or absence of EHNA (10 μM) on TNF-α and IL-6 production by LPS (2 μg/mL)-stimulated peritoneal macrophages were compared
with those of ANO. Levels of TNF-α and IL-6 in the culture supernatants were determined by ELISA after incubation for 24 h at 37°C (C and D).
Results are representative of three separate experiments with similar results (A and B). In (C) and (D), values represent the means ± S.D. of triplicate
cultures and are representative of two separate experiments with similar results. Inosine (←Adenosine) denotes amounts of inosine converted
from 10 μM adenosine by adenosine deaminase. *p < 0.05; **p < 0.01, significantly different when compared with control culture.
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had no effect on IL-6 secretion.
The synthetic agonists displayed different reactivities
to human THP-1 cells. ANO and the three agonists all
inhibited the release of both TNF-α and IL-6 by THP-1cells in response to LPS/huIFN-γ (Figure 5B). CGS21680
was most efficient. The inhibitory action of ANO was
comparable to those of the other two agonists, CCPA
and IB-MECA. The inhibitory effects by these agents did































































Figure 5 Comparison of anti-inflammatory activities of ANO and AR-selective agonists. Peritoneal macrophages (5 × 104/well) were
stimulated with LPS (1 μg/mL) and muIFN-γ (10 IU/mL) in the presence or absence of various concentrations of ANO or A1 AR-, A2A AR- and A3
AR-selective agonists (CCPA, CGS21680 and IB-MECA, respectively) at 37°C for 24 h (A). Sodium butyrate-treated THP-1 cells (1 × 105 /well) were
stimulated with LPS (5 μg/mL) plus huIFN-γ (500 IU/mL) in the presence or absence of various concentrations of ANO or AR-selective agonists at
37°C for 24 h (B). Levels of TNF-α, IL-6 and IL-12 in the culture supernatants were determined by ELISA. Values represent the percentage of
control culture. Results are representative of two separate experiments with similar results.
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or cell numbers at the concentrations employed as eval-
uated by trypan blue dye exclusion (data not shown).
Examination of the type of AR that was involved in the
anti-inflammatory actions of ANO
We examined which type of AR was involved in ANO-
mediated inhibition of pro-inflammatory cytokine produc-
tion, first by using murine peritoneal macrophages. An
A2A AR-selective antagonist (ZM241385) was unable to
abrogate ANO-mediated inhibitory effect, whereas 68% -
82% of recovery of adenosine-mediated TNF-α inhibition
was observed with ZM241385 (data not shown). We then
used a human monocytic cell line, THP-1, which had been
pretreated with 1 mM sodium butyrate for 4 days to
increase the response to 5 μg/mL LPS plus 500 IU/mL hu-
man IFN-γ (LPS/huIFN-γ) [24]. When sodium butyrate-pretreated THP-1 cells were stimulated with LPS/huIFN-
γ, substantial amounts of TNF-α (2.1 ng/mL) were de-
tected in the culture medium (Figure 6). Stimulation of
the THP-1 cells with LPS/huIFN-γ in the presence of
10 μM ANO resulted in a 73.6% decrease of TNF-α secre-
tion without inhibiting cell growth. Specifically, the num-
ber of cells per well averaged 1.36 ± 0.15 × 105 cells in the
LPS/huIFN-γ culture vs. 1.39 ± 0.11 × 105 cells in the LPS/
huIFN-γ plus 10 μM ANO culture. When THP-1 cells
were pretreated with 2 μM AR antagonists for 0.5 h prior
to stimulation with LPS/huIFN-γ in the presence of
10 μM ANO, slight but significant recoveries of TNF-α in-
hibition were observed with ZM241385 and MRS1911 (an
A3 AR antagonist) by 21% and 18%, respectively. Min-
imal but significant recoveries of TNF-α inhibition were
also observed with MRS1754 (an A2B AR antagonist)







Figure 6 Examination of the type of AR involved in the
anti-inflammatory activity of ANO. Sodium butyrate-treated THP-1
cells (1 × 105 /well) were pretreated with 2 μM of A1 AR-, A2A
AR-, A2B AR- and A3 AR-selective antagonists (DPCPX, ZM241385,
MRS1754 and MRS1911, respectively) for 30 min before stimulation
with LPS plus huIFN-γ in the presence of 10 μM ANO. After 24 h,
levels of TNF-α in the culture supernatants were determined by
ELISA. Values represent the means ± S.D. of triplicate cultures. Results
are representative of two separate experiments with similar results.
##, p < 0.01, significantly different when compared with vehicle
control culture in the presence of ANO.
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onists to 5 μM gave similar results (data not shown).
ANO reduced the lethality caused by LPS-induced
endotoxin shock
Since ANO efficiently reduced pro-inflammatory cytokine
secretion by LPS/muIFN-γ-stimulated macrophages, we
examined the anti-inflammatory actions of ANO in LPS-
induced endotoxin shock. When LPS was injected intra-
peritoneally (18 mg/kg) immediately after intravenous
administration of vehicle (PBS), all the mice died within
27 h (Figure 7A). In contrast, intravenous administration
of ANO (68 mg/kg and 135 mg/kg) immediately before
LPS injection reduced lethality in a dose-dependent man-
ner. Significant prolongation of survival was observed
upon administration of 135 mg/kg ANO, and 5 out of 6
mice were alive 3 days after LPS administration. We also
examined the effect of oral administration of ANO on
the survival of endotoxemic mice (Figure 7B). When
200 mg/kg of ANO was orally administered three times
(1 h before and 1 and 6 h after LPS injection), signifi-
cant prolongation of survival was observed and 6 out of
8 mice were alive after 3 days, whereas 7 out of 8 mice
died if treated with vehicle alone. Oral administration of
ANO 1 h before and 1 h after LPS injection resulted in
increased survival rates (Figure 7B), although the data
did not achieve statistical significance (p = 0.11).Since excessive production of pro-inflammatory cyto-
kines plays a critical role in animal models of septic
shock [25], we measured serum levels of pro-inflammatory
and anti-inflammatory cytokines 2 h after LPS adminis-
tration. In accordance with prolongation of survival,
serum levels of pro-inflammatory cytokines were sig-
nificantly decreased in a dose-dependent manner by
intravenous ANO administration (Figure 8A - C). In
particular, serum TNF-α levels were decreased by 94%
at 135 mg/kg of ANO administration (Figure 8A). With
regard to anti-inflammatory cytokine IL-10, it was
below detection in the sera of mice injected in-
travenously with PBS followed by intraperitoneal LPS
injection (Figure 8D). However, when ANO was admin-
istered intravenously just before LPS injection, serum
IL-10 levels were up-regulated and 14–19 ng/mL of IL-
10 were detected.ANO and adenosine differentially inhibited TNF-α secretion
by LPS-stimulated peritoneal macrophages
We found that ANO inhibited TNF-α secretion by LPS/
huIFN-γ-stimulated THP-1 cells partially through A2A
AR (Figure 7). Classical signaling through A2A AR de-
pends on its coupling to the heterotrimeric Gs protein
and stimulation of adenylyl cyclase, resulting in elevation
of intracellular levels of cyclic AMP (cAMP) [6-8]. We
observed that ANO increased cAMP levels in both peri-
toneal macrophages and a murine macrophage cell line,
RAW264.7 cells (data not shown). Elevation of cAMP in
RAW264.7 cells inhibited LPS-induced TNF-α production
via the protein kinase A (PKA)-dependent pathway [26].
Therefore, we examined the effect of a PKA inhibitor (H-
89) on adenosine- or ANO-induced inhibition of TNF-α se-
cretion by LPS-stimulated peritoneal macrophages. In this
experiment, to exclude extraneous signaling events exerted
by muIFN-γ, macrophages were stimulated with LPS only.
As shown in Figure 9A, adenosine-induced inhibition of
TNF-α secretion was recovered in a dose-dependent man-
ner by pre-incubation with H-89, and complete recovery
was observed with 5 μM H-89. However, H-89 had no ef-
fect on the ANO-induced inhibition of TNF-α secretion.
c-Fos protein induced by a Wortmannin-sensitive
kinase is responsible for the pro-inflammatory cytokine-
suppressive action of cAMP [27]. Peritoneal macrophages
were pretreated with Wartmannin before stimulation with
LPS in the presence of adenosine or ANO. Adenosine-
induced inhibition of TNF-α secretion was restored by
Wartmannin pretreatment in a dose-dependent manner
and complete recovery was observed at 0.5 μM Wartman-
nin (Figure 9B). Pretreatment with Wartmannin also sig-
nificantly restored the ANO-induced inhibition of TNF-α
secretion in a dose-dependent fashion, although the recov-


















Times after LPS injection (h)
**
B
Figure 7 LPS-induced endotoxin shock. BALB/c mice were intravenously administered saline or ANO (68 mg/kg or 135 mg/kg) immediately
before intraperitoneal injection with LPS (18 mg/kg) (n = 6 mice in each group) (A). In a separate experiment, ANO (200 mg/kg) was administered
orally 1 h before and 1 and 6 h after LPS injection (n = 8 mice in each group) (B). Survival of mice was monitored for 3 days after LPS injection.
Results are representative of two separate experiments with similar results. **p < 0.01, significantly different when compared with vehicle control.
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protein expression of c-Fos in LPS-stimulated RAW264.7
cells. As shown in Figure 10A, the c-fos mRNA expression
significantly increased 0.5 h after LPS stimulation in the
presence of 10 μM ANO compared with stimulation by
LPS alone. Expression of c-Fos protein was analyzed by
Western blotting. Because of multiple phosphorylation
sites, c-Fos was detected as multiple bands on SDS-PAGE
with different molecular weights [27]. As shown in
Figure 10B, ANO treatment caused a dose-dependent in-
crease in c-Fos protein expression 1 h after LPS stimula-
tion. c-Fos together with Jun family proteins constitutes
the dimeric transcription factor AP-1. However, ANO had
no effect on the expression of c-Jun protein.Discussion
In this study, we have shown that ANO is contained in
RJ, which has been widely consumed as a dietary supple-
ment and shows anti-inflammatory actions in vitro and
in vivo [17,28]. RJ contains AMP and its N1-oxide, AMP
N1-Oxide, both of which suppressed proliferation of rat
pheochromocytoma PC12 cells and stimulated expression
of neurofilament M [18]. It was also reported that RJ con-
tains adenosine [29]. Using two-dimensional gel electro-
phoresis, we previously showed that glucose oxidase is
present in RJ [30]. It is well known that glucose oxidase in
honey oxidizes glucose to gluconic acid and hydrogen per-
oxide, the latter of which acts as an anti-microbial agent
[31]. Therefore, it seems likely that ANO and AMP N1-






















Figure 8 Levels of pro-inflammatory and anti-inflammatory cytokines in the sera of endotoxemic mice. ANO was administered
intravenously as described in Figure 7A. Blood samples were collected from the abdominal aorta 2 h after LPS injection. Serum levels of TNF-α
(A), IL-6 (B), IL-12 (C) and IL-10 (D) were measured by ELISA. Values represent the means ± S.D. of six mice in each group. Results are representative of
two separate experiments with similar results. *p < 0.05; **p < 0.01, significantly different when compared with vehicle control.
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respectively, by hydrogen peroxide generated by glucose
oxidase.
In peritoneal macrophages, LPS/muIFN-γ upregulated
the production of both TNF-α and IL-6. This process was
significantly inhibited by adenine at concentrations ≥10
times of adenosine (Figure 2A and B), although the mech-
anism of action is unclear. Adenine N1-oxide also signifi-
cantly reduced pro-inflammatory cytokines. However, the
inhibitory action of adenine N1-oxide was comparable or
inferior to that of adenine. This outcome contrasts with
the superiority of ANO to adenosine in anti-inflammatory
functions. These results suggest that the ribose moiety
plays an essential role for manifestation of potent inhibi-
tory activity in ANO.
ANO inhibited IL-6 secretion by peritoneal macro-
phages stimulated by TLR 1/2, TLR 3 and TLR 4 agonists
(Figure 1). The effect of AR-selective agonists on cytokine
production by human mononuclear cells depends on the
TLR subtype [32]. For instance, CGS 21680 inhibited TLR4-mediated TNF-α release but potentiated TLR 3- and
TLR 5-mediated IL-6 release. In our study, we observed
that the effects of AR-selective agonists on cytokine pro-
duction were different depending on the pro-inflammatory
cytokines released even under the same stimulatory condi-
tions. Furthermore, functional differences between species
in the anti-inflammatory actions of these agonists were ob-
served. Both CCPA and CGS21680 significantly inhibited
TNF-α secretion but potentiated IL-6 and IL-12 secretion
by peritoneal macrophages stimulated with LPS/muIFN-γ,
while these two agonists inhibited both TNF-α and IL-6 se-
cretion by LPS/huIFN-γ-stimulated THP-1 cells (Figure 5).
However, ANO efficiently inhibited all of those pro-
inflammatory cytokines under the same stimulatory condi-
tions. These results suggest that the anti-inflammatory
effects of ANO are not restricted to a particular pro-
inflammatory cytokine or to a situation in which a specific
pathogen was involved.
At present, the differences in the response of the two
agonists (CCPA and CGS21680) to mouse and human
















































Figure 9 Effect of H-89 or Wartmannin on ANO-induced inhibition of TNF-α production. Peritoneal macrophages were incubated with
various concentrations of H-89 (A) or Wartmannin (B) for 30 min before stimulation with LPS (2 μg/mL) in the presence of absence of ANO
(1 μM) or adenosine (2.5 μM). After 24 h, levels of TNF-α in the culture supernatants were determined by ELISA. Values represent the means ± S.D.
of quadruplicate cultures. Results are expressed as the percentage of TNF-α released from macrophages in response to LPS and are representative
of two separate experiments with similar results. ƒƒ, p < 0.01, significantly different when compared with LPS stimulation in the absence of
adenosine or ANO. *p < 0.05; **p < 0.01, significantly different when compared with vehicle control culture in the presence of adenosine.
#, p < 0.05; ##, p < 0.01, significantly different when compared with vehicle control culture in the presence of ANO.
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shown that the signaling pathways used by the A2A re-
ceptor may vary with the cellular background and the
signaling machinery that the cell possesses [33]. Further-
more, species differences in the order of potency of A2A
AR agonists have been reported [34]. These findings
may provide insight for understanding the differential
responses observed in our study.
We examined the role of ARs in ANO-mediated inhib-
ition of TNF-α secretion by LPS/huIFN-γ-stimulated
THP-1 cells. We found evidence for the involvement of
all four ARs, although the extent of recoveries of TNF-α
inhibition was different among the four AR-selective an-
tagonists. Although still controversial, there is evidence
that the four ARs can be effective in the treatment of in-
flammatory disorders, including ischemia-reperfusion injur-
ies, endotoxin-induced injuries, arthritis and colitis. The
protective effects of A1 AR have been demonstrated in
models of ischemia reperfusion- and endotoxin-induced
lung injury [35,36]. Due to its pre-dominant expression in
immune cells and immunoregulatory actions, A2A AR has
been shown to have high potential in the treatment of
ischemia-, immune-, and inflammation-induced tissue
injury [8,9]. Although it remains controversial whether
A2B AR is pro-inflammatory or anti-inflammatory, re-
cent studies using A2B AR-deficient mice showed that
A2B AR played therapeutic roles in endotoxin-induced
lung injury [15,37]. A3 AR activation inhibited of TNF-α
release by endotoxin-stimulated monocyte/macrophage
lineage cells [38] in accordance with our findings using IB-
MECA.A common feature of the above results suggests that ac-
tivation of the four ARs might exert anti-inflammatory ef-
fects in TLR 4-mediated responses. In fact, CCPA,
CGS21680 and IB-MECA significantly inhibited TNF-α
production by LPS/IFN-γ-stimulated peritoneal macro-
phages and THP-1 cells (Figure 5). A2B AR-selective
agonist with an adenosine-like structure was not available
in our study. It is therefore not surprising that ANO-
mediated inhibition of TNF-α release was slightly but sig-
nificantly recovered by the four AR-selective antagonists.
However, since the activation of A2B AR and A3 AR
elicits a pro-inflammatory response in non-monocyte/
macrophage lineage cells [39,40], this issue has to be taken
into account for clinical application of ANO.
As expected from the in vitro results, intravenous
ANO administration significantly reduced the lethality
of LPS-induced endotoxin shock (Figure 7A). In marked
contrast and as reported previously [41], adenosine
failed to protect mice against endotoxin-induced mor-
tality in our study, which is probably due to its rapid
metabolism in vivo (data not shown). Reduced lethality
in mice was also observed when ANO was administered
orally before and after LPS injection (Figure 7B), sug-
gesting that ANO could exert its anti-inflammatory ef-
fects systemically through oral administration.
In the LPS-induced endotoxin shock model, serum
levels of pro-inflammatory cytokines (TNF-α, IL-6 and IL-
12) were reduced but the levels of anti-inflammatory cyto-
kine were upregulated by intravenous administrations of
ANO (Figure 8). In a manner similar to that observed by













































Figure 10 Effect of ANO on mRNA and protein expression of c-Fos in LPS-stimulated RAW264.7 cells. RAW264.7 cells were treated with
LPS (2 μg/mL) and ANO (10 μM) for the indicated times. c-fos mRNA was analyzed by real-time PCR (A). c-Fos and c-Jun proteins were assessed
by immunoblotting (B).
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(18 mg/kg) downregulated serum levels of TNF-α and IL-
6 and upregulated IL-10 levels in serum when determined
2 h after LPS injection (data not shown). Pro-inflammatory
cytokines TNF-α, IL-1 and IL-12, which are derived from
monocyte/macrophages, play a key role in the pathogenesis
of endotoxin shock [25]. In turn, anti-inflammatory cyto-
kine IL-10 plays a protective role by inhibiting pro-
inflammatory cytokines in LPS-induced endotoxin shock
[42]. Therefore, it is most likely that the decrease in pro-
inflammatory cytokines and upregulation of IL-10 explain
the reduced lethality achieved by ANO injection.
The difference in the doses of ANO between in vitro
and in vivo studies requires discussion. IB-MECA pre-
vents lethality in endotoxemic mice when injected at
0.5 mg/kg 30 min before administration of a lethal dose
of LPS [43]. In our study, a dose of 135 mg/kg of ANO
was necessary to significantly prolong survival in endo-
toxemic mice, although ANO was comparable to or
more potent than IB-MECA in suppressing the release
of pro-inflammatory cytokines in vitro (Figure 5). ANO
was refractory to adenosine-mediated conversion to in-
osine and therefore was stable in mouse serum (Figure 4
and data not shown). However, serum levels of ANO
gradually decreased when ANO was incubated in vitro
in blood taken from normal mice (data not shown).
When ANO was added to the blood taken from mice
injected with adenosine transport blocker dipyridamole,
the decrease in serum levels of ANO was significantly
inhibited (data not shown). These results suggest that
ANO might be taken up through an adenosine trans-
porter. The uptake of ANO through an adenosine trans-
porter might be one reason why high-dose ANO was
necessary in in vivo experiments. Structural modificationof ANO to prevent its uptake by an adenosine transporter
might decrease the effective dose in vivo. Studies are on-
going to address this issue.
Although ANO and adenosine are structurally similar,
ANO’s capacity to inhibit pro-inflammatory cytokine
production was much more potent than that of adeno-
sine (Figure 2). Refractoriness of ANO to adenosine de-
aminase might be a plausible explanation for the potent
anti-inflammatory activity of ANO (Figure 4B). However,
anti-inflammatory activity of adenosine in the presence
of EHNA was still inferior to that of ANO (Figure 4C
and D), suggesting the existence of another functional
difference between ANO and adenosine.
The intracellular signaling pathways induced by ANO
and adenosine seem to differ. In LPS-stimulated peritoneal
macrophages, ANO-mediated inhibition of TNF-α pro-
duction was not reversed by H-89, whereas adenosine-
mediated inhibition of TNF-α was completely recovered by
H-89 (Figure 9). In accordance with our results, the
non-selective AR agonist adenosine-5’-N-ethylcarboxa-
mide (NECA) inhibited TNF-α production by LPS-
stimulated murine macrophages via a signaling pathway
that was independent of PKA and exchange protein ac-
tivated by cAMP (Epac) [44].
Another cAMP-mediated suppressive mechanism of
LPS-induced pro-inflammatory cytokine production in-
volves the transcription factor c-Fos. c-Fos protein, which
is upregulated by cAMP and stabilized following phos-
phorylation by LPS-activated Ikkβ, physically binds to the
p65 subunit of NF-κB. Through this binding, the recruit-
ment of p65:p65 homodimer to the TNF-α promoter
region is reduced, resulting in the suppression of TNF-α
production [27]. Induction of c-fos mRNA was partially
suppressed by the phosphoinositide-3 kinase (PI3K)
Kohno et al. Journal of Inflammation  (2015) 12:2 Page 15 of 16inhibitor Wortmannin but not by the PI3K inhibitor
LY294002, suggesting a role of a Wortmannin-sensitive
kinase in the induction of c-fos mRNA [27]. The role of
c-Fos as an anti-inflammatory transcription factor was
reported previously [45]. Macrophages collected from
Fos−/− mice showed significantly enhanced production
of pro-inflammatory cytokines compared with macro-
phages from wild-type control mice [45]. In our study,
ANO-mediated inhibition of TNF-α production by
LPS-stimulated macrophages was partially recovered by
Wartmannin (Figure 9). Furthermore, we observed up-
regulation of c-fos mRNA and c-Fos protein expression
(Figure 10). These results suggest that up-regulation of
c-Fos is, at least in part, responsible for ANO-mediated
suppression of TNF-α production.
However, it should be noted that cAMP-mediated sup-
pression of IL-6 release was not complete and that re-
cruitment of p65 to the IL-6 promoter region was not
reduced but rather enhanced by cAMP treatment [27],
suggesting the presence of another mechanism for ANO-
induced suppression of IL-6 secretion. Experiments are
ongoing to address this issue.Conclusions
ANO is an oxidized product of adenosine at the N1
position of the adenine base moiety. Here, we have
shown that ANO is contained in RJ and that it pos-
sesses anti-inflammatory activities both in vitro and
in vivo. ANO was refractory to adenosine deaminase-
mediated conversion to inosine and exhibited potent
anti-inflammatory activities through signaling pathways
different from those of adenosine. ANO was superior to
GK2 (a common anti-inflammatory drug) in suppressing
broad spectrum inflammatory mediators. Reflecting the ef-
fective anti-inflammatory effects in vitro, intravenous ad-
ministration of ANO reduced lethality to LPS-induced
endotoxin shock. Significant increases in the survival
rate were also observed by oral administration of ANO,
although the most efficacious ANO dosage needs to be
addressed. These results suggest that ANO presents a
potential strategy for the treatment of inflammatory
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